Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Jefferies analyst Andrew Tsai maintains $Intra-Cellular Therapies(ITCI.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 56.4
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Intra-Cellular Therapies' (NASDAQ:ITCI) Investors Will Be Pleased With Their Fantastic 798% Return Over the Last Five Years
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
S&P 500 Futures Climb In Premarket Trading; Summit Therapeutics, Palantir Technologies Lead